| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 100,40 | 100,60 | 10:54 | |
| 100,40 | 100,80 | 10:52 |
Auslaufende Patente, geopolitische Risiken, Abschreibungen. Merck steht unter Druck, doch abseits der Schlagzeilen läuft das Geschäft erstaunlich gut.Den vollständigen Artikel lesen ...| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Merck pushes Keytruda across the FDA finish line for its first ovarian cancer nod | ||
| Mi | Merck's Keytruda Gets New FDA Approval For Expanded Use In Pretreated Ovarian Cancer Patients | ||
| Mi | FDA Approves Merck's Keytruda And Keytruda Qlx For Platinum-Resistant Ovarian Cancer | KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) on Wednesday said the U.S. Food and Drug Administration has approved Keytruda and Keytruda Qlx, a subcutaneous formulation of Keytruda, in combination... ► Artikel lesen | |
| Di | Merck's Keytruda gains additional indications for ovarian, fallopian tube carcinoma | ||
| Di | SA analyst upgrades/downgrades: TSLA, MRK, CRWD, STLA |
